Phase 1/2 Study Investigating Safety, Tolerability, Pharmacokinetics, And Preliminary Antitumor Activity Of Anti-Pd-L1 Monoclonal Antibody Bgb-A333 Alone And In Combination With Anti-Pd-1 Monoclonal Antibody Tislelizumab In Patients With Advanced Solid Tumors.

JOURNAL OF CLINICAL ONCOLOGY(2018)

引用 4|浏览6
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要